Structural and Mechanistic Insights into the Interaction of Cytochrome P4503A4 with Bromoergocryptine, a Type I Ligand.
Sevrioukova, I.F., Poulos, T.L.(2012) J Biol Chem 287: 3510-3517
- PubMed: 22157006 
- DOI: 10.1074/jbc.M111.317081
- Primary Citation of Related Structures:  
3UA1 - PubMed Abstract: 
Cytochrome P4503A4 (CYP3A4), a major human drug-metabolizing enzyme, is responsible for the oxidation and clearance of the majority of administered drugs. One of the CYP3A4 substrates is bromoergocryptine (BEC), a dopamine receptor agonist prescribed for the inhibition of prolactin secretion and treatment of Parkinson disease, type 2 diabetes, and several other pathological conditions ...